MarginsXMarginsX
Home › Markets › Health Care › ATOS

Atossa Therapeutics Inc. (ATOS)

ATOS trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$1.93
-1.53% on the day
Market cap
$19.3M
Nano cap
Revenue
No annual revenue filed since the period ending 2015-12-31
Net income
No annual revenue filed since the period ending 2015-12-31

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerATOS on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2012
SEC CIK0001488039

Financials

No annual revenue filed since the period ending 2015-12-31.

Warning signs

Cash runway
7.0 months
$20.6M cash at September 30, 2026
Share count, 1 year
+15.9%
2025-11-01 to 2026-11-02 · +19.5% over 3 years
Going-concern doubt
Yes
10-Q filed November 10, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"These conditions raise substantial doubt as to the Company's ability to continue as a going concern."
10-Q 2026-11-10
Cash and burn$20.6M cash; operating cash flow -$8.8M a quarter.Report 2026-09-30
Shares outstanding9,979,298 (2026-11-02); 129,171,424 a year earlier; 125,304,064 three years earlier. 1y figure adjusted for splits (1-for-15 overall); 3y figure adjusted for splits (1-for-15 overall).Cover page 2026-11-02
Reverse splits, 3 years1; latest 1-for-15 on 2026-02-02Source 2026-02-02
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the marketLatest 2026-06-12
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, Seattle, Washington, United StatesPCAOB Form AP 2026-04-06
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$5.6M-$5.5M$20.6MNo debt tagsNeeds four quarters10-Q 2026-11-10
Q2 2026
2026-06-30
Not filed-$8.5M-$9.6M$26.1MNo debt tagsNeeds four quarters10-Q 2026-11-10
Q1 2026
2026-03-31
Not filed-$9.6M-$9.6M$31.7MNo debt tagsNeeds four quarters10-Q 2026-11-10
Q4 2025
2025-12-31
Not filed-$10.9M-$10.5M$41.3MNo debt tagsNeeds four quarters10-K 2026-03-25
Q3 2025
2025-09-30
Not filed-$8.7M-$6.0M$51.8MNo debt tagsNeeds four quarters10-Q 2026-11-10
Q2 2025
2025-06-30
Not filed-$8.4M-$7.3M$57.9MNo debt tagsNeeds four quarters10-Q 2026-11-10
Q1 2025
2025-03-31
Not filed-$6.7M-$6.0M$65.1MNo debt tagsNeeds four quarters10-Q 2026-11-10
Q4 2024
2024-12-31
Not filed-$6.3M-$7.1M$71.1MNo debt tagsNeeds four quarters10-K 2026-03-25

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

The SEC filing list did not load in time for this page. It is on SEC EDGAR and in the full dossier.

Price moves

WindowReturn
1 week-7.5%
1 month-23.4%
3 months-23.4%
Year to date-77.9%
1 year-83.7%
From 52-week high-85.5%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
COCPCocrystal Pharma Inc.$0.9777-0.24%$18.8M
AYTUAytu BioPharma Inc.$1.82+1.68%$19.8M
CELUCelularity Inc.$0.6191-1.75%$20.1M
LPCNLipocine Inc.$1.66-2.92%$18.4M
SHPHShuttle Pharmaceuticals Holdings Inc.$4.24-6.40%$20.2M
IGCIGC Pharma Inc.$0.1750-0.57%$20.4M
CPHIChina Pharma Holdings Inc.$0.4800-7.35%$20.7M
TXMDTherapeuticsMD Inc.$1.81-3.21%$20.9M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier